These positive studies support the involvement of type 2 cytokines in driving PN disease pathogenesis and the targeting of the IL-4/IL-13 axis as a novel therapeutic paradigm for patients with PN. The gene discussed is IL4; the disease is poikiloderma with neutropenia.